Disturbance of Vancomycin Infusion Flow during Multidrug Infusion: Influence on Endothelial Cell Toxicity
Abstract
:1. Introduction
2. Results
3. Discussion
4. Materials and Methods
4.1. Cell Culture
4.2. Incubation with Vancomycin
4.2.1. Methodology to Study Concentration-Dependent Cytotoxicity
4.2.2. Methodology to Study Multi-Infusion-Dependent Cytotoxicity
4.3. Cytotoxicity Testing
4.4. Statistical Analysis
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
IV | intravenous |
PIV | peripheral intravenous |
HUVEC | Human umbilical vein endothelial cells |
VAN | vancomycin |
Highlights | |
Toxicity of variations in vancomycin concentration is explored. | |
Vancomycin-induced local endothelial toxicity is dose-dependent. | |
Variation of vancomycin concentration does not influence endothelial cell toxicity. | |
Medium removal simulating multi-drug infusion increases endothelial cell toxicity. |
References
- Peng, Y.; Li, C.-Y.; Yang, Z.-L.; Shi, W. Adverse reactions of vancomycin in humans: A protocol for meta-analysis. Medicine 2020, 99, e22376. [Google Scholar] [CrossRef]
- Bruniera, F.R.; Ferreira, F.M.; Saviolli, L.R.M.; Bacci, M.R.; Feder, D.; Pedreira, M.; Peterlini, M.A.S.; Azzalis, L.A.; Junqueira, V.B.C.; Fonseca, F.L. The use of vancomycin with its therapeutic and adverse effects: A review. Eur. Rev. Med. Pharmacol. Sci. 2015, 19, 694–700. [Google Scholar] [PubMed]
- Agence Nationale de Sécurité du Médicament et des Produits de Santé. Résumé des Caractéristiques du Produit Vancomycine 500 mg Poudre Pour Solution Pour Perfusion. Available online: http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0187161.htm (accessed on 17 December 2021).
- Talakoub, S.; Tork-Torabi, M.; Namnabati, M.; Allameh, Z. Vancomycin infusion methods on phlebitis prevention in children. Iran. J. Nurs. Midwifery Res. 2019, 24, 432–436. [Google Scholar] [CrossRef]
- Robibaro, B.; Vorbach, H.; Weigel, G.; Weihs, A.; Hlousek, M.; Presterl, E.; Georgopoulos, A.; Griesmacher, A.; Graninger, W. Endothelial cell compatibility of glycopeptide antibiotics for intravenous use. J. Antimicrob. Chemother. 1998, 41, 297–300. [Google Scholar] [CrossRef] [Green Version]
- Drouet, M.; Chai, F.; Barthelemy, C.; Lebuffe, G.; Debaene, B.; Décaudin, B.; Odou, P. Influence of Vancomycin Infusion Methods on Endothelial Cell Toxicity. Antimicrob. Agents Chemother. 2014, 59, 930–934. [Google Scholar] [CrossRef] [Green Version]
- Drouet, M.; Chai, F.; Barthelemy, C.; Lebuffe, G.; Debaene, B.; Décaudin, B.; Odou, P. Endothelial Cell Toxicity of Vancomycin Infusion Combined with Other Antibiotics. Antimicrob. Agents Chemother. 2015, 59, 4901–4906. [Google Scholar] [CrossRef] [Green Version]
- Lovich, M.A.; Doles, J.; Peterfreund, R.A. The Impact of Carrier Flow Rate and Infusion Set Dead-Volume on the Dynamics of Intravenous Drug Delivery. Anesth. Analg. 2005, 100, 1048–1055. [Google Scholar] [CrossRef] [PubMed]
- Timmerman, A.M.; Snijder, R.; Lucas, P.; Lagerweij, M.C.; Radermacher, J.H.; Konings, M.K. How physical infusion system parameters cause clinically relevant dose deviations after setpoint changes. Biomed. Tech. Eng. 2015, 60, 365–376. [Google Scholar] [CrossRef] [PubMed]
- Décaudin, B.; Dewulf, S.; Lannoy, D.; Simon, N.; Secq, A.; Barthélémy, C.; Debaene, B.; Odou, P. Impact of Multiaccess Infusion Devices on In Vitro Drug Delivery During Multi-Infusion Therapy. Anesth. Analg. 2009, 109, 1147–1155. [Google Scholar] [CrossRef] [PubMed]
- Lannoy, D.; Decaudin, B.; Simon, N.; Barthelemy, C.; Debaene, B.; Odou, P. The Impact on Drug Mass Flow Rate of Interrupting and Resuming Carrier Fluid Flow: An in vitro study on a very low dead-space volume infusion set. Anesth. Analg. 2012, 114, 328–332. [Google Scholar] [CrossRef] [PubMed]
- Millrose, M.; Kruse, M.; Flick, B.; Stahlmann, R. Effects of macrolides on proinflammatory epitops on endothelial cells in vitro. Arch. Toxicol. 2008, 83, 469–476. [Google Scholar] [CrossRef] [PubMed]
- Vorbach, H.; Weigel, G.; RobibaroO, B.; Armbruster, C.; Schaumann, R.; Hlousek, M.; Reiter, M.; Griesmacher, A.; Georgopoulos, A. Endothelial cell compatibility of clarithromycin for intravenous use. Clin. Biochem. 1998, 31, 653–656. [Google Scholar] [CrossRef]
- Curran, E.; Coia, J.; Gilmour, H.; McNamee, S.; Hood, J. Multi-centre research surveillance project to reduce infections/phlebitis associated with peripheral vascular catheters. J. Hosp. Infect. 2000, 46, 194–202. [Google Scholar] [CrossRef] [PubMed]
- Kozlovskaya, L.; Stepensky, D. Mechanisms of cell death induced by infusion sets leachables in in vitro experimental settings. Int. J. Pharm. 2015, 478, 693–701. [Google Scholar] [CrossRef] [PubMed]
- Hamid, R.; Rotshteyn, Y.; Rabadi, L.; Parikh, R.; Bullock, P. Comparison of alamar blue and MTT assays for high through-put screening. Toxicol. Vitr. 2004, 18, 703–710. [Google Scholar] [CrossRef] [PubMed]
- Rampersad, S.N. Multiple Applications of Alamar Blue as an Indicator of Metabolic Function and Cellular Health in Cell Viability Bioassays. Sensors 2012, 12, 12347–12360. [Google Scholar] [CrossRef] [PubMed]
Time | Condition 1: Fixed Concentration of Vancomycin without Medium Removal | Condition 2: Fixed Concentration of Vancomycin with Medium Removal | Condition 3: Variable Concentration of Vancomycin |
---|---|---|---|
H0 to H1 | VAN: 1X | VAN: 1X | VAN: 1X |
H1 to H2 | VAN: 1X | VAN = 0 mg/mL | |
H2 to H2.5 | VAN: 1X | VAN: 1X | |
H2.5 to H3 | VAN: 1X | VAN = 0 mg/mL | |
H3 to H4 | VAN: 1X | VAN: 1X | |
H4 to H5 | VAN: 1X | VAN = 0 mg/mL | |
H5 to H5.5 | VAN: 1X | VAN: 1X | |
H5.5 to H6 | VAN: 1X | VAN = 0 mg/mL | |
H6 to H6.5 | VAN: 1X | VAN: 1X | |
H6.5 to H7 | VAN: 1X | VAN: 3X | |
H7 to H7.5 | VAN: 1X | VAN: 1X | |
H7.5 to H8.5 | VAN: 1X | VAN = 0 mg/mL | |
H8.5 to H9 | VAN: 1X | VAN: 1X | |
H9 to H9.5 | VAN: 1X | VAN = 0 mg/mL | |
H9.5 to H10 | VAN: 1X | VAN: 1X |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Drouet, M.; Cuvelier, E.; Chai, F.; Genay, S.; Odou, P.; Décaudin, B. Disturbance of Vancomycin Infusion Flow during Multidrug Infusion: Influence on Endothelial Cell Toxicity. Antibiotics 2022, 11, 16. https://doi.org/10.3390/antibiotics11010016
Drouet M, Cuvelier E, Chai F, Genay S, Odou P, Décaudin B. Disturbance of Vancomycin Infusion Flow during Multidrug Infusion: Influence on Endothelial Cell Toxicity. Antibiotics. 2022; 11(1):16. https://doi.org/10.3390/antibiotics11010016
Chicago/Turabian StyleDrouet, Maryline, Elodie Cuvelier, Feng Chai, Stéphanie Genay, Pascal Odou, and Bertrand Décaudin. 2022. "Disturbance of Vancomycin Infusion Flow during Multidrug Infusion: Influence on Endothelial Cell Toxicity" Antibiotics 11, no. 1: 16. https://doi.org/10.3390/antibiotics11010016
APA StyleDrouet, M., Cuvelier, E., Chai, F., Genay, S., Odou, P., & Décaudin, B. (2022). Disturbance of Vancomycin Infusion Flow during Multidrug Infusion: Influence on Endothelial Cell Toxicity. Antibiotics, 11(1), 16. https://doi.org/10.3390/antibiotics11010016